Not even the release of a positive announcement has been able to stop the Recce Pharmaceuticals Ltd (ASX: RCE) share price from dropping today.
In afternoon trade, the biotechnology company’s shares are down 2.5% to 94 cents.
What did Recce announce?
This afternoon Recce Pharmaceuticals announced that the European Patent Office has granted patents relating to Recce 327 (R327) and Recce 529 (R529).
R327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria. This includes their superbug forms.
Whereas R529 is a new synthetic polymer formulation with indication against viruses. Recce is currently undertaking initial studies of R529 to indicate any potential therapeutic effect against COVID-19.
What were the patents?
According to the release, the European Patent Office granted claims relating to the composition/method of manufacture of RECCE anti-infectives, the administration of R327 or R529 by oral, injection, inhalation, and transdermal dose applications, and the use of R327 or R529 for the treatment of viruses having a lipid envelope or coat. These includes coronaviruses, influenza viruses, HIV, hepatitis, Ross River and herpes viruses.
Management believes this is a big positive given the size of the European market. It notes that Europe represents one of the largest anti-viral therapies markets in the world, valued at US$11.40 billion (A$14.93 billion) in 2019. It is expected to reach US$21.12 billion (A$27.66 billion) by 2027.
Recce’s Chief Executive Officer, James Graham, said: “Recce’s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented global infectious disease crisis before us. Our market-monopolies reinforce our unique opportunity among a significant-range of both bacterial and viral pathogens.”
Today’s decline means the Recce share price is now down by 14% since the start of the year. Though, it is worth noting that it is up 275% over the last 12 months.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
More reading
- Here’s why the Recce (ASX:RCE) share price is racing higher today
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post Recce Pharmaceuticals (ASX:RCE) share price tumbles despite positive update appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/31tTesH
Leave a Reply